Recently, more novel treatments known as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their analogues (originally developed to treat diabetes) are increasingly used in treatment plans (22, 23, 24). This evidence concerns the gene GLP1R and diabetes mellitus.